Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Dark Matter Blog

JULY 16, 2021

My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

The Pharma Data

OCTOBER 14, 2020

Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

MARCH 23, 2022

Unfortunately, in a Phase 3 clinical trial, treatment with remdesivir did not make a difference in mortality for Ebola virus disease patients. Without the stop sign, viral transcription no longer follows the correct order, which has a negative impact on viral protein production,” says Fang.

Virus 52

Virus Small Molecule Protein Production Research 52

Codon

MARCH 20, 2023

Point-of-care peptide hormone production enabled by cell-free protein synthesis. Marine biofilm engineered to produce current in response to small molecules. Peroxisomal metabolic coupling improves fatty alcohol production from sole methanol in yeast. DeWinter MA. ACS Synthetic Biology. ACS Synthetic Biology.

Virus 52

Virus Engineering RNA DNA 52

Codon

MAY 30, 2023

Read Programming inactive RNA-binding small molecules into bioactive degraders. Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. ‘OK’ to start clinical trials. ACS Synthetic Biology. eClinicalMedicine. Fierce Biotech.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

Read Programming inactive RNA-binding small molecules into bioactive degraders. Read Engineered bacteria to accelerate wound healing: an adaptive, randomised, double-blind, placebo-controlled, first-in-human phase 1 trial. ‘OK’ to start clinical trials. ACS Synthetic Biology. eClinicalMedicine. Fierce Biotech.

DNA 52

DNA RNA Engineering Vaccine 52